奥达卡替对骨质疏松绝经后女性骨转换标志物的影响:LOFT 研究的事后分析
该事后分析与建模研究纳入完成 LOFT 试验 60 个月治疗的 112 例患者(奥达卡替 57 例、安慰剂 55 例),检测 10 种骨重塑标志物。奥达卡替持续降低骨吸收标志物、逐渐升高 sICTP 与 sTRAP5b,sCTx 在 12 个月内短暂降低并于第 48 个月回到基线,建模提示与较大分子量 CTx 片段(含 sICTP)蓄积有关;骨形成标志物前 6 个月部分降低、48–60 个月接近基线。
要点
- 奥达卡替持续降低 sNTx、uNTx/Cr、uαα-与 uββCTx/Cr 及 uDPD/Cr,并逐渐升高 sICTP 与 sTRAP5b。
- sCTx 在奥达卡替组 12 个月内短暂降低,第 48 个月回到基线。
- 建模提示奥达卡替组 sCTx 变化主要源于较大 CTx 片段(含 sICTP)蓄积增加。
核心结论
- 骨转换标志物的变化支持奥达卡替持续直接抑制破骨细胞骨吸收活性而不抑制破骨细胞生成。
- 长期评估强调奥达卡替在破骨细胞胶原处理及随后成骨细胞骨形成方面的独特机制。
研究设计与样本
- LOFT 研究(NCT00529373)的事后分析与建模研究,纳入完成 60 个月治疗的患者 112 例(奥达卡替 57 例、安慰剂 55 例)。
- 在基线与第 6–60 个月检测 10 种骨重塑标志物:sCTx、uααCTx/Cr、uββCTx/Cr、uNTx/Cr、sNTx、uDPD/Cr、sICTP、sTRAP5b、sPINP 与 sBSAP。
- 因 CrossLaps® CTx 检测可识别 CTx 肽及包括 ICTP 在内的较大分子量含 CTx 肽,建立最佳拟合模型解释奥达卡替组 sCTx 的一过性降低。
主要发现
- 从基线至第 60 个月,奥达卡替较安慰剂持续降低骨吸收标志物 sNTx、uNTx/Cr、uααCTx/Cr、uββCTx/Cr 与 uDPD/Cr。
- 从基线至第 60 个月,奥达卡替较安慰剂逐渐升高靶点结合标志物 sICTP 与破骨细胞数量标志物 sTRAP5b。
- 奥达卡替组 sCTx 在 12 个月内短暂降低,第 48 个月回到基线;建模提示该变化主要由于较大 CTx 片段(包括 sICTP)蓄积增加。
- 骨形成标志物 sPINP 与 sBSAP 在前 6 个月较安慰剂部分降低,第 48–60 个月接近基线。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This post hoc analysis and modeling study examined the mechanism of action of odanacatib using a statistical model to explain sCTx response in ODN-treated patients as a function of other bone-turnover biomarkers that, with other observed biomarker changes, showed that odanacatib persistently inhibited osteoclastic bone removal activity without preventing osteoclastogenesis. INTRODUCTION: Odanacatib (ODN) is an oral selective cathepsin K (CatK) inhibitor, previously in development for osteoporosis treatment. A post hoc analysis examined ODN's mechanism of action on bone-turnover biomarkers. METHODS: A subset of patients who completed 60 months' treatment in the Long-Term Odanacatib Fracture Trial (LOFT; NCT00529373) (N = 112 [57 ODN, 55 placebo]) were evaluated. Serum (s) and urine (u) samples were assayed at baseline and months 6-60 for 10 known bone-remodeling biomarkers: sCTx, uαα- and uββCTx/Cr, uNTx/Cr, sNTx, uDPD/Cr, sICTP, sTRAP5b, sPINP, and sBSAP. Because the CrossLaps® CTx assay identifies the CTx peptide as well as larger molecular weight CTx-containing peptides, including ICTP, a best-fit model was developed to explain the transient sCTx reduction in ODN-treated patients. RESULTS: ODN persistently reduced the bone-resorption markers sNTx, uNTx/Cr, uαα- and uββCTx/Cr, and uDPD/Cr, and gradually increased the target-engagement marker sICTP and osteoclast number (sTRAP5b), versus placebo from baseline to month 60. sCTx was transiently reduced with ODN within 12 months, returning to baseline by month 48. Modeling suggested that sCTx changes in the ODN group were primarily due to increased accumulation of larger CTx species, including sICTP. The bone-formation markers sPINP and sBSAP showed partial reductions, versus placebo, in the first 6 months but approached baseline by months 48-60. CONCLUSION: Observed changes in bone-turnover biomarkers support the persistent efficacy of ODN in direct inhibition of osteoclastic bone-resorption activity, without inhibition of osteoclastogenesis. Long-term evaluation also underscores the unique mechanism of ODN on osteoclastic collagen processing and subsequently osteoblastic bone formation. TRIAL REGISTRATION: NCT00529373.
引用
- Duong LT, Clark S, Pickarski M, et al. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study. Osteoporos Int. 2022. PMID: 35711006. doi:10.1007/s00198-022-06406-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。